Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole vs amphotericin B for HIV-related Talaromyces marneffei infection
ChiCTR2100054081Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in talaromycosis and human immunodeficiency virus infection (HIV) comparing Voriconazole induction with Amphotericin B induction (2 arms). Primary endpoints: 14 days all-cause mortality and 24 weeks all-cause mortality. Started Jan 2022; status: recruiting.
02
Drugs
voriconazoleamphotericin b
03
Conditions
talaromycosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2100054081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054081.